This page contains brief information about enasidenib mesylate and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
Use in Cancer
Enasidenib mesylate is approved to treat:
- Acute myeloid leukemia (AML) that has recurred (come back) or is refractory (does not respond to treatment). It is used in adult patients whose AML has a mutation in the isocitrate dehydrogenase-2 (IDH2) gene.
Enasidenib mesylate is also being studied in the treatment of other types of cancer.
More About Enasidenib Mesylate
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
Research Results and Related Resources
Clinical Trials Accepting Patients
Find Clinical Trials for Enasidenib Mesylate - Check for trials from NCI's list of cancer clinical trials now accepting patients.